164: PARIS: a phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC).
Authors
Kordbacheh, TianaChan, Clara
Bossons, Amy
Franks, K
McDonald, F
Forster, M
Mendes, R
Quezada, S
Dovedi, Simon J
Ralph, C
Popat, S
Harrington, Kevin
Melcher, A
Popple, Amy
Illidge, Timothy M
Faivre-Finn, Corinne
Affiliation
Clinical Oncology, The Christie NHS Foundation Trust and University of Manchester, ManchesterIssue Date
2017-01
Metadata
Show full item recordCitation
164: PARIS: a phase I study of pembrolizumab anti-PD-1 monoclonal antibody in combination with radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC). 2017, 103:S75 Lung CancerJournal
Lung CancerDOI
10.1016/S0169-5002(17)30214-3Additional Links
http://linkinghub.elsevier.com/retrieve/pii/S0169500217302143Type
Meetings and ProceedingsLanguage
enISSN
01695002ae974a485f413a2113503eed53cd6c53
10.1016/S0169-5002(17)30214-3